Earnings results for NGM Biopharmaceuticals (NYSE:NGM)
NGM Biopharmaceuticals, Inc. is estimated to report earnings on 11/10/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.39. The reported EPS for the same quarter last year was $-0.17.
NGM Biopharmaceuticals last posted its earnings results on August 12th, 2020. The reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.08. The company had revenue of $19.76 million for the quarter, compared to analyst estimates of $20.42 million. NGM Biopharmaceuticals has generated $0.00 earnings per share over the last year. NGM Biopharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 10th, 2020 based off prior year’s report dates.
Analyst Opinion on NGM Biopharmaceuticals (NYSE:NGM)
8 Wall Street analysts have issued ratings and price targets for NGM Biopharmaceuticals in the last 12 months. Their average twelve-month price target is $31.38, predicting that the stock has a possible upside of 65.57%. The high price target for NGM is $39.00 and the low price target for NGM is $28.00. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”
NGM Biopharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $31.38, NGM Biopharmaceuticals has a forecasted upside of 65.6% from its current price of $18.95. NGM Biopharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: NGM Biopharmaceuticals (NYSE:NGM)
NGM Biopharmaceuticals does not currently pay a dividend. NGM Biopharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: NGM Biopharmaceuticals (NYSE:NGM)
In the past three months, NGM Biopharmaceuticals insiders have bought 140.00% more of their company’s stock than they have sold. Specifically, they have bought $2,090,995.00 in company stock and sold $871,250.00 in company stock.
Earnings and Valuation of NGM Biopharmaceuticals (NYSE:NGM
More latest stories: here